Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Earnings Preview: Cytokinetics (CYTK) Q3 Earnings Expected to Decline

by Zacks Equity Research

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

PacBio Aims to Expand Multiomic Capabilities Via Latest Innovations

by Zacks Equity Research

PACB unveils new SPRQ-Nx chemistry to cut sequencing costs and boost multiomic features on Revio and Vega.

Zacks Equity Research

Will Positive Regulatory Updates Further Boost INCY Stock?

by Zacks Equity Research

Incyte's strong 2025 performance is fueled by Jakafi's sustained growth and label expansion of Opzelura.

Zacks Equity Research

Oculis Holding AG (OCS) Soars 6.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Oculis Holding AG (OCS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

QGEN vs. ACAD: Which Stock Is the Better Value Option?

by Zacks Equity Research

QGEN vs. ACAD: Which Stock Is the Better Value Option?

Moumi Mondal headshot

Hologic Expands Panther Fusion's Menu With Diagnostic Innovation

by Moumi Mondal

HOLX expands its Panther Fusion platform with new GI bacterial assays, securing FDA and EU approvals to boost Diagnostics growth.

Moumi Mondal headshot

How to Play HOLX Stock This Breast Cancer Awareness Month?

by Moumi Mondal

Hologic's breast health innovations, AI breakthroughs and leadership moves signal optimism ahead despite macro headwinds.

Zacks Equity Research

Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker

by Zacks Equity Research

ILMN partners with pharma leaders to advance KRAS-focused companion diagnostics through its TruSight Oncology platform.

Zacks Equity Research

Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing

by Zacks Equity Research

DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.